Merck & Co. (MRK) announced a strategic collaboration and license agreement with Moderna Therapeutics to develop and commercialize novel messenger RNA (mRNA)-based personalized cancer vaccines. The collaboration will combine Merck�s established leadership in immuno-oncology with Moderna�s pioneering mRNA vaccine technology and GMP manufacturing capabilities to advance individually tailored cancer vaccines for patients across a spectrum of cancers. The companies believe that the mRNA-based personalized cancer vaccines� ability to specifically activate an individual patient�s immune system has the potential to be synergistic with checkpoint inhibitor therapies, including Merck�s anti-PD-1 therapy, KEYTRUDA (pembrolizumab).